{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T23:40:44Z","timestamp":1790293244215,"version":"4.1.0"},"reference-count":34,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Glucagon-like peptide-1 (GLP-1) is an incretin hormone involved in glucose regulation. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used in the treatment of type 2 diabetes mellitus and obesity, as well as in cardiovascular risk reduction. Recent evidence suggests that GLP-1 receptors are expressed in cutaneous tissues; however, their role in skin homeostasis and aging remains insufficiently clarified. This review summarizes recent experimental and clinical studies examining the effects of GLP-1 receptor agonists on skin homeostasis, wound healing, regeneration, and aging processes. Experimental data indicate that GLP-1 RAs may promote wound healing through modulation of inflammatory pathways, enhancement of keratinocyte migration, improved microvascular perfusion, and support of fibroblast function. Antioxidant and cytoprotective mechanisms have also been described. Conversely, rapid weight loss associated with GLP-1 RA therapy has been linked to structural facial changes, including reduction in dermal white adipose tissue and decreased collagen synthesis, which may clinically resemble accelerated skin aging. Mechanistic findings suggest heterogeneous and pathway-dependent effects. Overall, the impact of GLP-1 receptor agonists on skin biology appears multifaceted, and further well-designed clinical studies are required to determine their precise dermatological implications.<\/jats:p>","DOI":"10.3390\/jcm15082944","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T08:49:02Z","timestamp":1776070142000},"page":"2944","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effects of Glucagon-like Peptide-1 Receptor Agonists on Skin Homeostasis and Skin Aging Processes"],"prefix":"10.3390","volume":"15","author":[{"given":"Gabriel\u0117","family":"\u017daliukait\u0117","sequence":"first","affiliation":[{"name":"Pharmacy and Pharmacology Center, Faculty of Medicine, Vilnius University, LT-01513 Vilnius, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noura","family":"Lebbar","sequence":"additional","affiliation":[{"name":"Aesthetic Medicine, University of Genoa, 16126 Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"ref_1","first-page":"42","article-title":"A Review of glucagon-like peptide-1 in dermatology","volume":"18","author":"Patino","year":"2025","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"ref_2","first-page":"e78575","article-title":"A system-based review on effects of glucagon-like peptide-1 receptor agonists: Benefits vs. risks","volume":"17","author":"Fadel","year":"2025","journal-title":"Cureus"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e16716","DOI":"10.1111\/jocd.16716","article-title":"The Role of GLP-1 Agonists in esthetic medicine: Exploring the impact of semaglutide on body contouring and skin health","volume":"24","author":"Haykal","year":"2025","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1111\/jdv.20694","article-title":"The effects of GLP-1RA on inflammatory skin diseases: A comprehensive review","volume":"39","author":"Paschou","year":"2025","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Patel, S., and Niazi, S.K. (2025). Emerging frontiers in GLP-1 therapeutics: A comprehensive evidence base. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17081036"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"ojaf022","DOI":"10.1093\/asjof\/ojaf022","article-title":"Glucagon-like peptide-1 receptor agonists: Friend or foe of aesthetic medicine?","volume":"7","author":"Rosenbloom","year":"2025","journal-title":"Aesthet. Surg. J. Open Forum"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Anastasiou, I.A., Tentolouris, A., Sarantis, P., Katsaouni, A., Rebelos, E., Mourouzis, I., Pantos, C., and Tentolouris, N. (2025). Semaglutide enhances cellular regeneration in skin and retinal cells in vitro. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17091115"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: Mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1007\/s12020-025-04293-w","article-title":"GLP-1RA and the possible skin aging","volume":"89","author":"Paschou","year":"2025","journal-title":"Endocrine"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Persson, C., Eaton, A., and Mayrovitz, H.N. (2025). A Closer Look at the Dermatological Profile of GLP-1 Agonists. Diseases, 13.","DOI":"10.3390\/diseases13050127"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1159\/000544023","article-title":"Dermatologic implications of glucagon-like peptide-1 receptor agonist medications","volume":"11","author":"Burke","year":"2025","journal-title":"Skin Appendage Disord."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"q1645","DOI":"10.1136\/bmj.q1645","article-title":"GLP-1 agonists: US sees 700% increase over four years in number of patients without diabetes starting treatment","volume":"386","author":"Mahase","year":"2024","journal-title":"BMJ"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Gratzl, S., Rodriguez, P.J., Cartwright, B.M.G., Baker, C., and Stucky, N.L. (2024). Monitoring Report: GLP-1 RA Prescribing Trends\u2014December 2023 Data. medRxiv.","DOI":"10.1101\/2024.01.18.24301500"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"48","DOI":"10.20431\/2456-0022.0802005","article-title":"A Systematic Review of the Cutaneous Adverse Effects of GLP-1 Agonists","volume":"8","author":"DeVore","year":"2025","journal-title":"ARC J. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Cao, K. (2025). GLP-1 RAs and skin health: Exploring dermatologic side effects and therapeutic interventions. Preprints.","DOI":"10.20944\/preprints202506.1838.v1"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"84","DOI":"10.25259\/CSDM_97_2025","article-title":"Semaglutide and the skin: A brief review of dermatologic implications","volume":"5","author":"Salam","year":"2025","journal-title":"Cosmoderma"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1055\/a-2148-6321","article-title":"Implications of ozempic and other GLP-1 receptor agonists for facial plastic surgeons","volume":"39","author":"Humphrey","year":"2023","journal-title":"Facial Plast. Surg."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.bjps.2024.07.051","article-title":"The rise of \u201cozempic face\u201d: Analyzing trends and treatment challenges associated with rapid facial weight loss induced by GLP-1 agonists","volume":"96","author":"Mansour","year":"2024","journal-title":"J. Plast. Reconstr. Aesthet. Surg."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.36849\/JDD.7613","article-title":"Natural weight loss or \u201cozempic face\u201d: Demystifying a social media phenomenon","volume":"23","author":"Carboni","year":"2024","journal-title":"J. Drugs Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s00424-017-1953-7","article-title":"The role of macrophages in skin homeostasis","volume":"469","author":"Yanez","year":"2017","journal-title":"Pfl\u00fcg. Arch. Eur. J. Physiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1111\/jocd.16155","article-title":"Skin homeostasis: Mechanism and influencing factors","volume":"23","author":"Jiao","year":"2024","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1007\/s12325-025-03257-w","article-title":"GLP-1 receptor agonists, DPP-4 inhibitors and the skin\u2014Diabetes meets dermatology: A brief narrative review","volume":"42","author":"Pantazopoulos","year":"2025","journal-title":"Adv. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.diabres.2018.10.013","article-title":"Glucagonlike peptide-1 analogue liraglutide facilitates wound healing by activating PI3K\/akt pathway in keratinocytes","volume":"146","author":"Nagae","year":"2018","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1111\/dom.15721","article-title":"Incretin-based therapy and the risk of diabetic foot ulcers and related events","volume":"26","author":"Werkman","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"113236","DOI":"10.1016\/j.biopha.2022.113236","article-title":"Application of glucagon-like peptide-1 receptor antagonists in fibrotic diseases","volume":"152","author":"Yang","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ejphar.2018.10.053","article-title":"Anti-inflammatory and prohealing impacts of exendin-4 treatment in zucker diabetic rats: Effects on skin wound fibroblasts","volume":"842","author":"Wolak","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"15834","DOI":"10.1038\/s41598-018-34160-w","article-title":"Transcriptomic and functional network features of lung squamous cell carcinoma through integrative analysis of GEO and TCGA data","volume":"8","author":"Li","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jss.2016.09.024","article-title":"Exendin-4, a glucagon-like peptide-1 analogue, accelerates diabetic wound healing","volume":"208","author":"Roan","year":"2017","journal-title":"J. Surg. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"81-LB","DOI":"10.2337\/db23-81-LB","article-title":"81-LB: Novel microsphere technology reducing injection site reaction in the development of long-acting GLP-1 RA formulation","volume":"72","author":"Kim","year":"2023","journal-title":"Diabetes"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1007\/s00125-019-4918-x","article-title":"Locally delivered GLP-1 analogues liraglutide and exenatide enhance microvascular perfusion in individuals with and without type 2 diabetes","volume":"62","author":"Aung","year":"2019","journal-title":"Diabetologia"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"13411","DOI":"10.1038\/s41598-021-92712-z","article-title":"Assessing the impact of aging and blood pressure on dermal microvasculature by reactive hyperemia optical coherence tomography angiography","volume":"11","author":"Casper","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.jbiosc.2022.06.004","article-title":"Synergistic effect of glucagon-like peptide-1 analogue liraglutide and ZnO on the antibacterial, hemostatic, and wound healing properties of nanofibrous dressings","volume":"134","author":"Wu","year":"2022","journal-title":"J. Biosci. Bioeng."},{"key":"ref_33","first-page":"S1","article-title":"Anti-aging data and support claims-consensus statement","volume":"3","author":"Elsner","year":"2011","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1093\/asj\/sjae132","article-title":"Decoding the implications of glucagon-like peptide-1 receptor agonists on accelerated facial and skin aging","volume":"44","author":"Ridha","year":"2024","journal-title":"Aesthet. Surg. J."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/8\/2944\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T09:52:57Z","timestamp":1776073977000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/8\/2944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":34,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["jcm15082944"],"URL":"https:\/\/doi.org\/10.3390\/jcm15082944","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]}}}